Recommendations for the treatment of psoriatic arthritis


Authors: J. Štolfa;  J. Vencovský;  K. Pavelka
Authors‘ workplace: Revmatologický ústav Praha
Published in: Čes. Revmatol., 24, 2016, No. 4, p. 142-152.
Category: Recomendation

Overview

The last recommendations for the treatment and monitoring of psoriatic arthritis were published by the Czech Society for Rheumatology five years ago, in 2011 [1]. Since then there has been a rapid evolution of new knowledge on all aspects of psoriatic disease, especially with regards to the extra-articular manifestations (enthesitis, dactylitis) and the comorbidities (especially metabolic syndrome, and cardiovascular disease). With a certain delay, compared to rheumatoid arthritis, attention was focused on a new treatment strategy aimed at early treatment initiation and determination of therapeutic targets. At the same time, we have witnessed an intensive research of new biological original drugs (boDMARDs) with a different mechanism of action than the inhibition of TNFα (eg. inhibitors of the p40 subunit of IL-12 / 23-ustekinumab, and inhibitors of IL-17 – secukinumab and ixekizumab), small molecules for oral administration (eg. inhibitor of phosphodiesterase 4 - apremilast, an inhibitor of JAK – tofacitinib), and finally, the introduction of biosimilar biological drugs (bsDMARDs). Following a similar update of EULAR recommendations, these aspects have raised the need to update the Recommendations of the Czech Society for Rheumatology as well.

Key words:
psoriatic arthritis, enthesitis, dactylitis, treatment recommendations, treatment strategy, activity indices, targets for therapy, biological therapy of PsA, ​​early treatment


Sources

1. Štolfa J, Vencovský J, Pavelka K. Doporučené postupy České revmatologické společnosti pro léčbu psoriatické artritidy. Čes. Revmatol 2011; 19 (No.1): 11–16.

2. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: develop-ment of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–73.

3. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263–69.

4. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008; 35: 469–71.

5. Haroon M, Gallagher P, Fitzgerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2014; published online Feb 13. DOI:10.1136/annrheumdis-2013-204858.

6. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48–53.

7. Coates LC, Helliwell PS. Validation of minimal disease activity (MDA) criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010; 62: 965–69.

8. Coates LC, Helliwell PS. Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 2010; 49: 1793–94.

9. Coates LC, Moverley AR, McParland L., et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Published online October 1, 2015 http://dx.doi.org/10.1016/S0140-6736(15)00347-5.

10. Schoels M, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2015. Published Online First 12 Aug 2015. doi: 10.1136/annrheumdis-2015-207507.

11. Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009; 68: 823–7.

12. Aletaha D, Funovits J, Breedveld FC, et al. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009; 60: 1242–9.

13. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387–94.

14. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012 Jan; 71: 4–12.

15. Gossec L, Smolen JS, Ramiro S. et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies 2015 update. Ann Rheum Dis 2015; 0: 1–12.

16. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015. Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.

17. Štolfa J, Pavelka K, Vencovský J. Standardní postupy v léčbě psoriatické artritidy. Čes Revmatol 2005; 3: 97–105.

18. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015; 27: 118–26.

19. Di Minno MND, Ambrosino P, Lupoli R, et al. Cardiovascular risk markers in patients with psoriatic arthritis: a meta-analysis of literature studies. Ann Med 2015; 47: 346–53.

20. Blair HA, Dhillon S. Secukinumab: A review in ankylosing spondylitis. Drugs 2016; 76(10): 1023–30.

21. Ibrahim GH, Groves C, Chandramohan Mm et al. Clinical and ultrasound validation of the Leeds Enthesitis Index in psoriatic arthritis and rheumatoid arthritis. Rheumatol 2011; 731917 [Epub 2011 May 4].

22. Levin D, Nazarian L, Miller T, et al. Lateral epicondylitis of the elbow: US findings. Radiology 2005; 237: 230–4.

23. Gladman DD, Cook RJ, Schentag C, et al. The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondylarthritis research consortium of Canada. J Rheumatol 2004; 31: 1126–31.

24. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, et al. International spondyloarthritis interobserver reliability exercise – the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007; 34(8): 1740–5.

25. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Annals of the Rheumatic Diseases 2011; 70(2): 272–277, 2011.

Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account